sci-tech-ez-600x235

Cutting edge biomedical companies expand research at Sci-Tech Daresbury

Posted on 22 August 2013 · Posted in News

Three biomedical companies in Sci-Tech Daresbury Enterprise Zone have secured £1.5 million of investment to advance their innovative work and research.

Perfectus Biomed Limited, Tomorrow’s Medicines and Arcis-Altos Group have each attracted new funding from a range of public and private sector sources.

John Downes, Chief Executive of Langtree and Director of the Sci-Tech Daresbury joint venture board, said:

“Companies based at Sci-Tech Daresbury are often operating at the cutting edge of industry, developing game-changing products and services which will have a significant impact on the way we live our day-to-day lives over the next decade or so.

“The 3 businesses on site which have most recently secured investment are operating in the fast-growing, rapidly-evolving biomedical sector and their innovative approach, coupled with a real depth of commercial awareness, creates a very attractive package for investors.”

Perfectus Biomed will expand its research team and help them meet growing demand for testing; and following its successes with clinical trial patients in 82 countries, Tomorrow’s Medicines has been funded to develop its online platform yourtreatmentchoices.com.

For Arcis-Altos Group, this funding will support the companies research and development, comes in addition to £1 million of funding achieved earlier this month. Peter Whitehurst, CEO at Arcis-Altos Group, said:

“We’re delighted to have achieved these two significant funding boosts. This investment demonstrates real confidence in the role that our technology could play in the molecular diagnostics sector. Arcis is clearly viewed as having winning technology to contribute to further growth in the global biomedical sector.”

Another 7 companies in the Enterprise Zone have been rewarded for their innovation and potential for growth by being chosen to take part in the Technology Strategy Board Launchpad programme, which aims to accelerate growth of companies within the sector.

Sci-Tech Daresbury Business Development Manager, John Leake, said:

“Public sector funding has an important role to play in ensuring that companies which have a truly pioneering and relevant offer are supported as they bring that technology or service to market.

“This is especially crucial for high-quality, high-tech SME companies of the sort that are based at Sci-Tech Daresbury and we’re delighted to see campus companies raising the investment they need to develop their product base and take their technology forward.”

Sci-Tech Daresbury is a world class location for high-tech business and leading edge science based in Cheshire. It provides a unique environment for innovation and business growth, with knowledge sharing, collaboration and networking.

The Enterprise Zone has the potential to create up to 15,000 skilled jobs, and provide funding for new specialist office, laboratory and technical space. Enterprise Zone status will also allow the campus to leverage more than £150 million in private sector investment.

For more information on Sci-Tech Daresbury Enterprise Zone see: http://www.sci-techdaresbury.com/.